NeuroBo Pharmaceuticals, Inc. GEMP Balance Sheet

Neurobo pharmaceuticals, inc. (GEMP)

Balance Sheet / Yearly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Dec'15
Assets
Current assets:
Cash
9,799	13,908	1,855	3,643	5,510	2,845	23,806	28,039	34,461	18,473	25,340	22,491	29,282	24,033	28,369	4,826	3,620
Restricted cash
15	15	15	15	15	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses
1,332	153	140	252	513	929	1,033	719	300	490	863	483	552	713	547	162	23
Deferred offering costs
-	-	-	-	-	-	9	-	-	21	-	-	-	-	-	-	-
Other assets
65	42	38	78	68	34	14	40	68	25	-	-	-	-	-	-	-
Deferred offering costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,730	-
Total current assets
11,211	14,118	2,048	3,988	6,106	3,808	24,862	28,798	34,829	19,009	26,203	22,974	29,834	24,746	28,916	6,718	3,643
Right-of-use assets and other
143	150	-	-	-	9	-	-	-	-	-	-	-	-	-	-	-
Property and equipment, net
181	200	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-
Other assets
-	-	-	-	-	-	-	-	-	-	8	30	-	-	-	-	-
Deferred offering costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	847
Deposits
-	-	-	26	52	-	8	8	8	8	-	-	8	8	8	8	-
Total assets
11,535	14,468	2,048	4,014	6,158	3,820	24,870	28,806	34,837	19,017	26,211	23,004	29,842	24,754	28,924	6,726	4,490
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable
1,273	638	2,677	1,668	1,234	170	2,351	2,569	2,848	4,025	4,332	3,464	3,541	2,008	1,257	642	531
Accrued liabilities
2,411	1,422	396	382	478	49	1,585	994	1,054	1,010	1,963	1,808	1,002	2,113	679	2,455	1,617
Lease liability, short-term
22	22	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Term loan - current portion
-	-	-	-	-	-	3,681	2,652	2,355	1,355	-	-	-	-	-	-	-
Convertible notes to related parties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4,256	1,795
Convertible notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6,833	4,629
Premium conversion derivative
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	243	345
Total current liabilities
3,706	2,082	3,073	2,050	1,712	219	7,617	6,215	6,257	6,390	6,295	5,272	4,543	4,121	1,936	14,429	8,917
Long-term liabilities:
Commitments and contingencies (Notes 5, 14 and 16)
-	-	-	-	-	118	-	-	-	-	-	-	-	-	-	-	-
Lease and other long-term liabilities
89	94	-	-	-	23	-	-	-	-	-	-	-	-	-	-	-
Term loan
-	-	-	-	-	-	6,398	7,540	7,760	8,683	9,964	-	-	-	-	-	-
Other liabilities
-	-	-	-	-	-	2	3	3	3	3	2	2	1	-	-	-
Total liabilities
3,795	2,176	3,073	2,050	1,712	360	14,017	13,758	14,020	15,076	16,262	5,274	4,545	4,122	1,936	14,429	8,917
Commitments and contingencies (Note 5)
-	-	-	-	-	-	0	0	0	-	0	-	-	0	-	-	0
Stockholders’ equity:
Redeemable convertible preferred stock (Series A and B), $0.0001 par value per share; 12,000,000 shares authorized and 4,801,020 issued and outstanding as of December 31, 2018; aggregate liquidation preference of $16,800 as of December 31, 2018. No shares authorized, issued or outstanding as of December 31, 2019.
-	-	-	-	-	16,746	-	-	-	-	-	-	-	-	-	8,252	7,953
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding as of March 31, 2020 and December 31, 2019.
-	-	-	-	-	-	0	0	0	-	0	-	-	0	-	-	0
Common stock, $0.001 par value per share, 100,000,000 shares authorized; 15,677,307 and 15,592,718 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively.
16	16	23	22	22	-	22	22	22	18	18	18	18	17	17	12	12
Additional paid–in capital
49,342	49,130	93,214	92,774	92,336	2,266	91,286	89,402	88,493	64,397	63,659	62,769	59,834	47,674	46,816	-	-
Accumulated other comprehensive (loss) income
-22	12	-	-	-	2	-	-	-	-	-	-	-	-	-	-	-
Accumulated deficit
-41,596	-36,866	-94,262	-90,832	-87,912	-15,554	-80,455	-74,376	-67,698	-60,474	-53,728	-45,057	-34,555	-27,059	-19,845	-15,967	-12,392
Total stockholders’ equity
7,740	12,292	-1,025	1,964	4,446	-13,286	10,853	15,048	20,817	3,941	9,949	17,730	25,297	20,632	26,988	-15,955	-12,380
Total liabilities and stockholders’ equity
11,535	14,468	2,048	4,014	6,158	3,820	24,870	28,806	34,837	19,017	26,211	23,004	29,842	24,754	28,924	6,726	4,490